SOKVISETH MOENG

Mr. SOKVISETH MOENG

Institute of Biosciences and Technolgy, Texas A&M University, College Station, Texas, USA
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2019 in Cells
Verified
Journal Article
Open access
PDF file
HSHyun Ah Seo
Hyun Ah Seo
SOKVISETH MOENGSOKVISETH MOENG
SOKVISETH MOENG
SSSeokmin Sim
Seokmin Sim
HKHyo-Jeong Kuh
Hyo-Jeong Kuh
SCSoo Young Choi
Soo Young Choi
JPJong Kook Park
Jong Kook Park
The susceptibility of cancer cells to different types of treatments can be restricted by intrinsic and acquired therapeutic resistance, leading to the failure of cancer regression and remission. To overcome this problem, a combination therapy has been proposed as a fundamental strategy to improve therapeutic responses; however, resistance is still unavoidable. MicroRNA (miRNAs) are associated with cancer therapeutic resistance. The modulation of dysregulated miRNA levels through miRNA-based therapy comprising a replacement or inhibition approach has been proposed to sensitize cancer cells to other anti-cancer therapies. The combination of miRNA-based therapy with other anti-cancer therapies (miRNA-based combinatorial cancer therapy) is attractive, due to the ability of miRNAs to target multiple genes associated with the signaling pathways controlling therapeutic resistance. In this article, we present an overview of recent findings on the role of therapeutic resistance-related miRNAs in different types of cancer. We review the feasibility of utilizing dysregulated miRNAs in cancer cells and extracellular vesicles as potential candidates for miRNA-based combinatorial cancer therapy. We also discuss innate properties of miRNAs that need to be considered for more effective combinatorial cancer therapy.

Verified
Journal Article
Open access
PDF file
HLHan Yeoung Lee
Han Yeoung Lee
SSSeung Wan Son
Seung Wan Son
SOKVISETH MOENGSOKVISETH MOENG
SOKVISETH MOENG
SCSoo Young Choi
Soo Young Choi
JPJong Kook Park
Jong Kook Park
Cancer is a global health concern, and the prognosis of patients with cancer is associated with metastasis. Multistep processes are involved in cancer metastasis. Accumulating evidence has shown that cancer cells acquire the capacity of anoikis resistance and anchorage-independent cell growth, which are critical prerequisite features of metastatic cancer cells. Multiple cellular factors and events, such as apoptosis, survival factors, cell cycle, EMT, stemness, autophagy, and integrins influence the anoikis resistance and anchorage-independent cell growth in cancer. Noncoding RNAs (ncRNAs), such as microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), are dysregulated in cancer. They regulate cellular signaling pathways and events, eventually contributing to cancer aggressiveness. This review presents the role of miRNAs and lncRNAs in modulating anoikis resistance and anchorage-independent cell growth. We also discuss the feasibility of ncRNA-based therapy and the natural features of ncRNAs that need to be contemplated for more beneficial therapeutic strategies against cancer.

3 February 2020 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
SOKVISETH MOENGSOKVISETH MOENG
SOKVISETH MOENG
SSSeung Wan Son
Seung Wan Son
HSHyun Ah Seo
Hyun Ah Seo
JLJong Sun Lee
Jong Sun Lee
CKChung Kwon Kim
Chung Kwon Kim
JPJong Kook Park
Jong Kook Park
Background/Aim: MicroRNAs (miRNAs) play regulatory roles in pancreatic ductal adenocarcinoma (PDAC). However, it is still required to identify the function of miRNA-301-3p in pancreatic cancer cells. Materials and Methods: Effects of luteolin on cell growth, TRAIL cytotoxicity, and miR-301-3p levels were evaluated. The role of miRNA-301-3p in regulating cell proliferation, target gene expression, and TRAIL cytotoxicity were studied. Results: The levels of miR-301-3p were down-regulated in PANC-1 cells exposed to luteolin, which inhibits the growth of PANC-1 cells and sensitizes cells to TRAIL. The knockdown of miR-301-3p attenuates cell proliferation and enhances TRAIL cytotoxicity. In addition, caspase-8 was directly targeted by miR-301-3p. Conclusion: Our findings unveil a critical biological function of miR-301-3p in regulating cell proliferation and elevating an antiproliferative effect of TRAIL on cancer cells. Our observation of miR-301-3p/caspase-8 relationship can also serve to clarify the role of miR-301-3p in other cancer types and related diseases.

3 August 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
SOKVISETH MOENGSOKVISETH MOENG
SOKVISETH MOENG
SSSeung Wan Son
Seung Wan Son
JLJong Sun Lee
Jong Sun Lee
HLHan Yeoung Lee
Han Yeoung Lee
TKTae Hee Kim
Tae Hee Kim
JPJong Kook Park
Jong Kook Park
Pancreatic cancer is malignant and the seventh leading cause of cancer-related deaths worldwide. However, chemotherapy and radiotherapy are—at most—moderately effective, indicating the need for new and different kinds of therapies to manage this disease. It has been proposed that the biologic properties of pancreatic cancer cells are finely tuned by the dynamic microenvironment, which includes extracellular matrix, cancer-associated cells, and diverse immune cells. Accumulating evidence has demonstrated that extracellular vesicles (EVs) play an essential role in communication between heterogeneous subpopulations of cells by transmitting multiplex biomolecules. EV-mediated cell–cell communication ultimately contributes to several aspects of pancreatic cancer, such as growth, angiogenesis, metastasis and therapeutic resistance. In this review, we discuss the role of extracellular vesicles and their cargo molecules in pancreatic cancer. We also present the feasibility of the inhibition of extracellular biosynthesis and their itinerary (release and uptake) for a new attractive therapeutic strategy against pancreatic cancer.

14 October 2020 in Molecules
Verified
Journal Article
Open access
PDF file
SSSeung Wan Son
Seung Wan Son
HLHan Yeoung Lee
Han Yeoung Lee
SOKVISETH MOENGSOKVISETH MOENG
SOKVISETH MOENG
HKHyo-Jeong Kuh
Hyo-Jeong Kuh
SCSoo Young Choi
Soo Young Choi
JPJong Kook Park
Jong Kook Park
Cancer is a global health concern and one of the main causes of disease-related death. Even with considerable progress in investigations on cancer therapy, effective anti-cancer agents and regimens have thus far been insufficient. There has been compelling evidence that natural phytochemicals and their derivatives have potent anti-cancer activities. Plant-based anti-cancer agents, such as etoposide, irinotecan, paclitaxel, and vincristine, are currently being applied in medical treatments for patients with cancer. Further, the efficacy of plenty of phytochemicals has been evaluated to discover a promising candidate for cancer therapy. For developing more effective cancer therapy, it is required to apprehend the molecular mechanism deployed by natural compounds. MicroRNAs (miRNAs) have been realized to play a pivotal role in regulating cellular signaling pathways, affecting the efficacy of therapeutic agents in cancer. This review presents a feature of phytochemicals with anti-cancer activity, focusing mainly on the relationship between phytochemicals and miRNAs, with insights into the role of miRNAs as the mediators and the regulators of anti-cancer effects of phytochemicals.

5 November 2018 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
SOKVISETH MOENGSOKVISETH MOENG
SOKVISETH MOENG
HSHyun Ah Seo
Hyun Ah Seo
CHCho Yean Hwang
Cho Yean Hwang
GCGabriel A. Cipolla
Gabriel A. Cipolla
DLDong Jin Lee
Dong Jin Lee
JPJong Kook Park
Jong Kook Park
Background/Aim: Patients with advanced non-small cell lung cancer (NSCLC) frequently face a dismal prognosis because of lack of curative therapies. We, therefore, conducted a preclinical investigation of the therapeutic efficacy of microRNA-107 (miR-107). Materials and Methods: The effects of miR-107 on cell proliferation and target gene expression were studied. Combinatorial effects of miR-107 and parthenolide were evaluated. Results: Cell proliferation was repressed in A549 NSCLC cells transfected with miR-107. Inhibitor of nuclear factor kappa B kinase subunit gamma was directly targeted by miR-107. Overexpression of miR-107 in A549 cells sensitized them to parthenolide along with a marked reduction of cyclin-dependent kinase 2. Conclusion: Our findings unveil an important biological function of miR-107 in regulating lung cancer cell proliferation and elevating an antiproliferative effect of parthenolide on lung cancer cells, suggesting that miR-107 could be beneficial benefit treatment for advanced NSCLC.